Moderna receives $50 million from CEPI for Bundibugyo Ebola vaccine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
June 1, 2026 5:00 AM EDTCoalition for Epidemic Preparedness Innovations funding builds on Moderna's prior filovirus research and supports preclinical development and Phase 1 clinical evaluation
CAMBRIDGE, MA / ACCESS Newswire / June 1, 2026 / Moderna, Inc. (NASDAQ: MRNA) today announced an expanded collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a potential vaccine against Bundibugyo ebolavirus (BDBV), a cause of Ebola virus disease for which there are currently no licensed vaccines indicated.
Under the agreement, CEPI has... More
